Fortress Biotech (NASDAQ:FBIO) Receives New Coverage from Analysts at StockNews.com

StockNews.com started coverage on shares of Fortress Biotech (NASDAQ:FBIO – Free Report) in a report published on Thursday morning. The firm issued a hold rating on the biopharmaceutical company’s stock. Separately, Cantor Fitzgerald reaffirmed an overweight rating and set a $75.00 price target on shares of Fortress Biotech in a research report on Tuesday, August […]

Related Keywords

,Sigma Securities ,Fortress Biotech Company Profile ,Envestnet Asset Management Inc ,Cantor Fitzgerald ,Securities Exchange Commission ,Wells Fargo Company ,Advisor Group Holdings Inc ,Fortress Biotech Inc ,Fortress Biotech ,Free Report ,Get Free Report ,Exchange Commission ,Group Holdings ,Envestnet Asset Management ,Fortress Biotech Daily ,Nasdaq Fbio ,Fbio ,Medical ,21976u10 ,Initiated Coverage ,Stocknews Com ,